Clinical trial
A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who…
NCT00038636 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00038636 |
|---|---|
| Title | A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors |
| Official title | A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Lopinavir/ritonavir, Ritonavir |
| Enrollment | 36 |
| Start date | Sep 1, 2000 |
| First posted | Jun 4, 2002 |
| Last update posted | Aug 15, 2006 |
| Countries | France, Spain, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: